1. Red-sea Dolomite as a Sustainable Catalyst in the Synthesis of bis-Indolyl methanes with Molecular Docking Validation as HIV-1 Replication Inhibitor. Abdelghany, M. and T.K. Khatab. Bulletin of the Chemical Society of Ethiopia, 2021. 35(3): p. 647-657. ISI[000765427500002].
[WOS]. HIV_03_2022.
2. Conformational Stabilization of gp41-Mimetic Miniproteins Opens up New Ways of Inhibiting HIV-1 Fusion. Cano-Muñoz, M., J. Lucas, L.Y. Lin, S. Cesaro, C. Moog, and F. Conejero-Lara. International Journal of Molecular Sciences, 2022. 23(5): 2794. PMID[35269936]. PMCID[PMC8911282].
[PubMed]. HIV_03_2022.
3. Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-specific Antibody Leronlimab in Two Species. Chang, X.L., J.S. Reed, G.M. Webb, H.L. Wu, J. Le, K.B. Bateman, J.M. Greene, C. Pessoa, C. Waytashek, W.C. Weber, J. Hwang, M. Fischer, C. Moats, O. Shiel, R.M. Bochart, H. Crank, D. Siess, T. Giobbi, J. Torgerson, R. Agnor, L. Gao, K. Dhody, J.P. Lalezari, I.S. Bandar, A.M. Carnate, A.S. Pang, M.J. Corley, S. Kelly, N. Pourhassan, J. Smedley, B.N. Bimber, S.G. Hansen, L.C. Ndhlovu, and J.B. Sacha. Plos Pathogens, 2022. 18(3): e1010396. PMID[35358290]. PMCID[PMC8970399].
[PubMed]. HIV_03_2022.
4. Impact of Combinations of Clinically Observed HIV Integrase Mutations on Phenotypic Resistance to Integrase Strand Transfer Inhibitors (INSTIs): A Molecular Study. Cheung, P.K., A. Shahid, W. Dong, K.J. Lepik, J.S.G. Montaner, M.A. Brockman, Z.L. Brumme, and C.J. Brumme. Journal of Antimicrobial Chemotherapy, 2022. 77(4): p. 979-988. PMID[35061879].
[PubMed]. HIV_03_2022.
5. The Thiazole-5-carboxamide GPS491 Inhibits HIV-1, Adenovirus, and Coronavirus Replication by Altering RNA Processing/Accumulation. Dahal, S., R. Cheng, P.K. Cheung, T. Been, R. Malty, M.L.S. Geng, S. Manianis, L. Shkreta, S. Jahanshahi, J. Toutant, R. Chan, S. Park, M.A. Brockman, M. Babu, S. Mubareka, K. Mossman, A. Banerjee, S. Gray-Owen, M. Brown, W.A. Houry, B. Chabot, D. Grierson, and A. Cochrane. Viruses, 2022. 14(1): 60. PMID[35062264]. PMCID[PMC8779516].
[PubMed]. HIV_03_2022.
6. Voacanga globosa SpirobisIndole Alkaloids Exert Antiviral Activity in HIV Latently Infected Cell Lines by Targeting the NF-kB Cascade: In Vitro and in Silico Investigations. de Jesus, M.S.M., A.P.G. Macabeo, J.D.A. Ramos, V.O. de Leon, K. Asamitsu, and T. Okamoto. Molecules, 2022. 27(3): 1078. PMID[35164343]. PMCID[PMC8840767].
[PubMed]. HIV_03_2022.
7. A Fragment Integrational Approach to GPCR Inhibition: Identification of a High Affinity Small Molecule CXCR4 Antagonist. Fang, X., Q. Meng, H. Zhang, X. Fang, L.S. Huang, X. Zhang, R.T. Schooley, A. Ciechanover, J. An, Y. Xu, and Z. Huang. European Journal of Medicinal Chemistry, 2022. 231: 114150. PMID[35124530].
[PubMed]. HIV_03_2022.
8. Design, Synthesis and X-ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-furofuran Derivatives as P2 Ligands. Ghosh, A.K., S. Kovela, A. Sharma, D. Shahabi, A.K. Ghosh, D.R. Hopkins, M. Yadav, M.E. Johnson, J. Agniswamy, Y.F. Wang, S.I. Hattori, N. Higashi-Kuwata, M. Aoki, M. Amano, I.T. Weber, and H. Mitsuya. ChemMedChem. PMID[35170223].
[PubMed]. HIV_03_2022.
9. Selection and Identification of an RNA Aptamer That Specifically Binds the HIV-1 Capsid Lattice and Inhibits Viral Replication. Gruenke, P.R., R. Aneja, S. Welbourn, O.B. Ukah, S.G. Sarafianos, D.H. Burke, and M.J. Lange. Nucleic Acids Research, 2022. 50(3): p. 1701-1717. PMID[35018437]. PMCID[PMC8860611].
[PubMed]. HIV_03_2022.
10. Bromodomain and Extra-terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection in Vitro and ex Vivo by Increasing CDK9 Phosphorylation and Recruitment. Huang, X.S., R.R. Tian, M.D. Ma, R.H. Luo, L.M. Yang, G.H. Peng, M. Zhang, X.Q. Dong, and Y.T. Zheng. Pharmaceuticals, 2022. 15(3): 338. PMID[35337136]. PMCID[PMC8952190].
[PubMed]. HIV_03_2022.
11. Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. Jecs, E., Y.A. Tahirovic, R.J. Wilson, E.J. Miller, M. Kim, V. Truax, H.H. Nguyen, N.S. Akins, M. Saindane, T. Wang, C.S. Sum, M.E. Cvijic, G.M. Schroeder, S.L. Burton, C.A. Derdeyn, L. Xu, Y. Jiang, L.J. Wilson, and D.C. Liotta. Journal of Medicinal Chemistry, 2022. 65(5): p. 4058-4084. PMID[35179893].
[PubMed]. HIV_03_2022.
12. Design, Synthesis, and Docking Studies of Thioimidazolyl diketoacid Derivatives Targeting HIV-1 Integrase. Karimi, N., R.V. Roudsari, Z. Hajimahdi, and A. Zarghi. Journal of Medicinal Chemistry, 2022. 18(5): p. 616-628. PMID[34587886].
[PubMed]. HIV_03_2022.
13. A Synthetic Resveratrol Analog Termed Q205 Reactivates Latent HIV-1 through Activation of P-TEFb. Liang, T., Z. Wu, Y. Li, C. Li, K. Zhao, X. Qiao, H. Duan, X. Zhang, S. Liu, B. Xi, and L. Li. Biochemical Pharmacology, 2022. 197: 114901. PMID[34971588].
[PubMed]. HIV_03_2022.
14. Anandenanthera colubrina (Vell.) Brenan as an Inhibitor of HIV-1 BaL Infection. Maia, C.M.A., S. Pasetto, J. Silva, J.F. Tavares, E. Costa, and R.M. Murata. Natural Product Research, 2022. 36(6): p. 1621-1625. PMID[33729064].
[PubMed]. HIV_03_2022.
15. Conserved Topology of Virus Glycoepitopes Presents Novel Targets for Repurposing HIV Antibody 2G12. Miller, N.L., V. Subramanian, T. Clark, R. Raman, and R. Sasisekharan. Scientific Reports, 2022. 12(1): 2594. PMID[35173180]. PMCID[PMC8850445].
[PubMed]. HIV_03_2022.
16. Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs. Naidu, B.N., M. Patel, B. McAuliffe, B. Ding, C. Cianci, J. Simmermacher, S. Jenkins, D.D. Parker, P. Sivaprakasam, J.A. Khan, K. Kish, H. Lewis, U. Hanumegowda, M. Krystal, N.A. Meanwell, and J.F. Kadow. Journal of Medicinal Chemistry, 2022. 65(6): p. 4949-4971. PMID[35235334].
[PubMed]. HIV_03_2022.
17. Effect of Manuka Honey on Human Immunodeficiency Virus Type 1 Reverse Transcriptase Activity. Obossou, E.K., Y. Shikamoto, Y. Hoshino, H. Kohno, Y. Ishibasi, T. Kozasa, M. Taguchi, I. Sakakibara, K. Tonooka, T. Shinozuka, and K. Mori. Natural Product Research, 2022. 36(6): p. 1552-1557. PMID[33550857].
[PubMed]. HIV_03_2022.
18. Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-catalytic Site Integrase Inhibitor JTP-0157602. Ohata, Y., M. Tomonaga, Y. Watanabe, K. Tomura, K. Kimura, T. Akaki, K. Adachi, E.N. Kodama, Y. Matsuzaki, and H. Hayashi. Journal of Virology, 2022. 96(6): e0184321. PMID[35045265]. PMCID[PMC8941924].
[PubMed]. HIV_03_2022.
19. Preliminary Safety Assessment of CIGB-210, an Investigational Peptide for HIV Infection. Ramirez-Suarez, A.C., T. Paneque-Guerrero, D. Casillas-Casanova, K. Cosme, D. Bacardi, C.A. Duarte, J. Ancizar, E. Brown, J. Castro, J. Suarez-Alba, H. Garay, K. Pereira, and C. Fernandez-Ortega. Human & Experimental Toxicology, 2022. 41: 9603271211073708. PMID[35112887].
[PubMed]. HIV_03_2022.
20. Across Functional Boundaries: Making Nonneutralizing Antibodies to Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells. Richard, J., D.N. Nguyen, W.D. Tolbert, R. Gasser, S.L. Ding, D. Vezina, S.Y. Gong, J. Prevost, G. Gendron-Lepage, H. Medjahed, S. Gottumukkala, A. Finzi, and M. Pazgier. mBio, 2021. 12(5): e0140521. PMID[34579568]. PMCID[PMC8546553].
[PubMed]. HIV_03_2022.
21. HIV-1 Integrase Inhibitory Effects of Major Compounds Present in CareVid™: An anti-HIV Multi-Herbal Remedy. Rotich, W., E. Mas-Claret, N. Sadgrove, A. Guantai, G.F. Padilla-González, and M.K. Langat. Life (Basel), 2022. 12(3): 417. PMID[35330168]. PMCID[PMC8950597].
[PubMed]. HIV_03_2022.
22. Engineering pan-HIV-1 Neutralization Potency through Multispecific Antibody Avidity. Rujas, E., H. Cui, J. Burnie, C.B. Aschner, T.T. Zhao, S. Insausti, K. Muthuraman, A. Semesi, J. Ophel, J.L. Nieva, M.S. Seaman, C. Guzzo, B. Treanor, and J.P. Julien. Proceedings of the National Academy of Sciences of the United States of America, 2022. 119(4): e2112887119. PMID[35064083]. PMCID[PMC8795538].
[PubMed]. HIV_03_2022.
23. Viremia Controls Env-specific Antibody-secreting Cell Responses in Simian Immunodeficiency Virus Infected Macaques Pre and Post-antiretroviral Therapy. Silveira, E.L.V., J.J. Hong, P.K. Amancha, K.A. Rogers, A.A. Ansari, S.N. Byrareddy, and F. Villinger. AIDS, 2021. 35(13): p. 2085-2094. PMID[34148985]. PMCID[PMC8490307].
[PubMed]. HIV_03_2022.
24. Discovery of Tricyclic HIV-1 Integrase-LEDGF/p75 Allosteric Inhibitors by Intramolecular Direct Arylation Reaction. Taoda, Y., T. Akiyama, K. Tomita, M. Fujiwara-Kitamura, Y. Tamura, T. Kawasuji, E. Matsuoka, E. Akihisa, T. Seki, and T. Yoshinaga. Bioorganic & Medicinal Chemistry Letters, 2022. 64: 128664. PMID[35272008].
[PubMed]. HIV_03_2022.
25. Single-chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission. van Dorsten, R.T., L. Reh, A. Trkola, L. Morris, and P.L. Moore. Journal of Virology, 2022. 96(4): e0193421. PMID[34935437]. PMCID[PMC8865436].
[PubMed]. HIV_03_2022.
26. Design, Synthesis and Biological Evaluation of Protease Inhibitors Containing Morpholine Cores with Remarkable Potency against Both HIV-1 Subtypes B and C. Zhu, M., H. Zhou, L. Ma, B. Dong, J. Ding, J. Zhou, J. Wang, G. Zhang, M. Wang, Q. Shan, S. Cen, and Y. Wang. European Journal of Medicinal Chemistry, 2022. 233: 114251. PMID[35278855].
[PubMed]. HIV_03_2022.
Patent Citations
27. Novel Dibenzoacridinium Derivatives, Their Process of Preparation and Their Use for Treating Viral Infections. Amrane, S., M.-A. Andreola, C. Olivier, and Y. Ferrand. Patent. 2022. 2021-EP75191 2022053704: 48pp.
[Patent]. HIV_03_2022.
28. Preparation of Dihydroquinazolin-2-one Derivatives as Selective Cytotoxic Agents Useful in the Treatment of HIV. Converso, A., A. El Marrouni, A.W. Shaw, D.N. Hunter, A. Forster, C. Wang, and Y. Zhang. Patent. 2022. 2021-US47460 2022046844: 109pp.
[Patent]. HIV_03_2022.